Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Arch Bronconeumol (Engl Ed) ; 55(7): 357-367, 2019 Jul.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30473265

RESUMO

INTRODUCTION: The usefulness of sericin as pleurodesis agent has previously been described. Present study aims to compare sericin pleurodesis regarding success, effectiveness, tolerability, and side-effects. METHODS: Adult, 12-week-old Wistar-albino rats (n=60), divided to five groups as sericin, talcum-powder, doxycycline, silver-nitrate and control. Agents were administrated through left thoracotomy, rats sacrificed twelve-days after. RESULTS: Highest ratio of collagen fibers was observed in sericin group, and the intensity was higher than talcum-powder group (p<0.05). Compared to silver nitrate, sericin group displayed better mesothelial reaction, and multi-layer mesothelium was also better (p<0.05). Foreign body reaction and emphysema were less frequent in sericin group (p<0.05). The presence of biological tissue in parenchyma was less prominent in sericin group (p<0.05). Foreign body reaction on thoracic wall was less common in sericin group (p<0.05). Presence of biological tissue glue in thoracic wall was less prominent in sericin group (p<0.05). Glomerular degeneration was lower in sericin group compared to the silver nitrate group (p<0.05), and tubular degeneration was less common in sericin group than talcum group (p<0.05). Pericarditis was less common in sericin group compared to the other groups (p<0.05). CONCLUSION: As an intrinsic, natural glue protein, sericin protects the lung parenchyma and tissues, and its glue-like characteristics enable pleurodesis. The success of sericin in pleurodesis was demonstrated in the present study based on investigations of the pleurae. Being cost-effective and better tolerated agent associated with a low potential of side effects, sericin is more effective, less expensive and provides more lung parenchyma protection.


Assuntos
Doxiciclina/uso terapêutico , Pleurodese/métodos , Soluções Esclerosantes/uso terapêutico , Sericinas/uso terapêutico , Nitrato de Prata/uso terapêutico , Talco/uso terapêutico , Animais , Colágeno/análise , Análise Custo-Benefício , Doxiciclina/economia , Doxiciclina/toxicidade , Avaliação Pré-Clínica de Medicamentos , Enfisema/induzido quimicamente , Epitélio/efeitos dos fármacos , Epitélio/patologia , Fibrose , Reação a Corpo Estranho/induzido quimicamente , Pulmão/efeitos dos fármacos , Pulmão/patologia , Masculino , Miocárdio/química , Pleura/efeitos dos fármacos , Pleura/patologia , Pleurodese/efeitos adversos , Pleurodese/economia , Ratos , Ratos Wistar , Soluções Esclerosantes/economia , Soluções Esclerosantes/toxicidade , Sericinas/economia , Sericinas/toxicidade , Nitrato de Prata/economia , Nitrato de Prata/toxicidade , Talco/economia , Talco/toxicidade , Toracotomia , Vísceras/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA